Midatech Pharma PLC Announces Receipt of NASDAQ Notice

February 3, 2023 5:30 AM

ABINGDON, OXFORDSHIRE / ACCESSWIRE / February 3, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"), dated 31 January 2023, stating that the Company is not in compliance with the minimum bid price requirement set forth...

Read more

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

February 1, 2023 8:15 AM

Company's biologic drug candidate targets a key pathway involved in the progression and maintenance of depigmentation.TORONTO, ON / ACCESSWIRE / February 1, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has received approval from Health Canada for a Phase 2 clinical study of the company's EB06 monoclonal antibody candidate as a...

Read more

Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock

February 1, 2023 8:05 AM

SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each...

Read more

Aqualung Therapeutics Concludes ALT-100 Antibody (mAb) Dosing in Its P1a Study with no Reported SAE's. Will Engage FDA for Clearance of the P2a PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients

January 31, 2023 11:55 AM

Aqualung has selected Novotech as their CRO partner to conduct the P2a PUERTA study in moderate/severe ARDS subjects.Expected screening for enrolled subjects to begin April/May 2023.Aqualung Submitting an end of P1 (EOP1) meeting data packet to the FDA in February based on preliminary results of the P1a Healthy Human Volunteer study.TUCSON, AZ / ACCESSWIRE / January 31, 2023 / Aqualung Therapeutics, an early stage immunotherapeutics company with...

Read more

Change in the Number of Shares and Votes in BioInvent International AB

January 31, 2023 4:27 AM

LUND, SE / ACCESSWIRE / January 31, 2023 / BioInvent International (STO:BINV)Lund, Sweden, January 31, 2023 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per January 31, 2023 amounts to 65,804,362 shares, corresponding to an equal number of votes.The increase in the number of shares and votes results from the directed issue of USD 3 million...

Read more

DiviTum(R) TKa Clinical Validation Data Published in Biomarkers

January 31, 2023 3:20 AM

UPPSALA, SE / ACCESSWIRE / January 31, 2023 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer diagnostics, today announces that results clinically validating the DiviTum® TKa assay have been published in the scientific journal Biomarkers. The results, from an analysis of samples and clinical data from the SWOG S0226 study, support the use of DiviTum® TKa when monitoring metastatic breast cancer...

Read more

Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £4,056,250

January 26, 2023 2:00 AM

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). IN ADDITION, MARKET SOUNDINGS WERE...

Read more

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

January 25, 2023 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer.The completion of dosing for...

Read more

InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Dr. Christopher Prior, as CEO and Reports Recent Drug Discovery Highlights

January 24, 2023 3:00 PM

ZURICH, SWITZERLAND / ACCESSWIRE / January 24, 2023 / InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces the appointment of Dr. Christopher Prior as Chief Executive Officer. In his new role, Dr. Prior will be responsible for leading the company into its next stage of development and global expansion.Dr. Christopher Prior is a highly accomplished serial entrepreneur who has built...

Read more

Statera Biopharma Announces Completion of Application Process to Uplist to the OTCQB(R) Venture Marketplace

January 24, 2023 9:45 AM

FORT COLLINS, CO / ACCESSWIRE / January 24, 2023 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has completed the application process for moving off the OTC Pink Sheets and uplisting to the OTCQB® Venture Marketplace. The application process will not guarantee...

Read more

Midatech Pharma PLC Announces Result of General Meeting

January 23, 2023 7:35 AM

Result of General MeetingAppointment of Specialist Business Advisory Firm - QuantumaABINGDON, OXFORDSHIRE / ACCESSWIRE / January 23, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that at its General Meeting held at 10.00 a.m. today all ordinary resolutions were carried, but all other resolutions were not passed by...

Read more

Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T 3rd Process Qualification Run Completed

January 23, 2023 2:00 AM

LONDON, UK / ACCESSWIRE / January 23, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its third Process Qualification ("PQ") run of the end-to-end process for the manufacture of HEMO-CAR-T cells. The process was carried out in the Company's current Good Manufacturing Practice ("cGMP") compliant clean...

Read more

SeqOnce Biosciences Completes Relocation to Carlsbad, CA

January 19, 2023 6:00 AM

New Research Facility to Advance GenomicsCARLSBAD, CA / ACCESSWIRE / January 19, 2023 / SeqOnce Biosciences, Inc., a genomics company creating new tools to detect and analyze human disease, is thrilled to announce it has officially completed their move into a new facility located in Carlsbad, CA. This move will significantly improve their research capabilities allowing them to expand the development of assay panels, improve detection...

Read more

Adolore Biotherapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

January 18, 2023 10:00 AM

Live video webcast presentation on Thursday, January 19th at 10:00 AM ETDELRAY BEACH, FL / ACCESSWIRE / January 18, 2023 / Adolore Biotherapeutics, Inc. ("Adolore" or the "Company") a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for pain, today announced that Roelof Rongen, CEO of Adolore, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023...

Read more

The Problem of Biodiversity Loss: How It Relates to Climate, and What the Countries of the World Are Doing About It

January 18, 2023 9:50 AM

NORTHAMPTON, MA / ACCESSWIRE / January 18, 2023 / Ray C. Anderson FoundationHumans are the primary cause of the accelerated rate of biodiversity loss around the globe. The current statistics are sobering, and the urgency we must feel to solve the problem is only heightened when you examine the links between biodiversity and our changing climate. Fortunately, there's been some positive recent momentum in the form of international biodiversity...

Read more

enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer

January 18, 2023 8:05 AM

Dr. Alavi is a highly accomplished medical device executive with proven track record of successfully leading R&D, Quality Assurance, Regulatory Affairs, and Manufacturing organizations across a number of companies within the cardiac and vascular spaceIRVINE, CA / ACCESSWIRE / January 18, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease,...

Read more

BioInvent Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program and Receives $3 million Strategic Equity Investment

January 17, 2023 2:15 PM

Strategic equity investment of USD 3 million to support clinical advancement of BI-1206 in Non-Hodgkin's LymphomaSupports also clinical development of BI-1808 in cutaneous T-cell lymphomaLLS TAP is a strategic funding initiative to accelerate innovative blood cancer therapeuticsLUND, SWEDEN / ACCESSWIRE / January 17, 2023 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and...

Read more

Adolore Biotherapeutics Strengthens Management Team and Board of Directors with the Appointments of Roelof Rongen, MSE, MBA and Mark C. Rogers, MD, MBA

January 17, 2023 10:30 AM

Mr. Rongen appointed as CEO and member of the Board bringing 30 years of executive leadership experience and expertise across a number of therapeutic areasBolstered expertise on Board of Directors with addition of Dr. Rogers who brings significant leadership and expertise spanning both public and private sectors in health care and the biopharmaceutical industryDELRAY BEACH, FL / ACCESSWIRE / January 17, 2023 / Adolore Biotherapeutics, Inc....

Read more

Qrons Announces Engagement of Israeli Intellectual Property Law Firm IPK to Develop Roadmap for Its New Product Line

January 17, 2023 9:00 AM

NEW YORK, NY / ACCESSWIRE / January 17, 2023 / Qrons Inc. (OTCQB:QRON) announced today that it had engaged with the intellectual property law firm IPK, an Israeli firm with unique expertise in medical-related intellectual property development and protection. Working closely with IPK will enable Qrons to tailor an intellectual property strategy and roadmap addressing its new product line. Qrons has previously worked with IPK founder Dr. Paul...

Read more

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

January 17, 2023 8:30 AM

Study successfully identified lowest effective dose1.0% formulation reached primary endpoint with statistical significanceCompany preparing for End of Phase 2 meeting with FDA following full analysisTORONTO, ON / ACCESSWIRE / January 17, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced preliminary, topline results from a Phase 2b clinical...

Read more